BioSpace News Archive

Adaptation Health is calling for earlier-stage, healthcare entrepreneurs (both for-profit and non-profit) and innovators nationwide to present their ideas for the Medicaid Innovation Challenge.

Mentice today announced the appointment of Dr. David J. Ballard as Chief Clinical Officer and Executive Vice President of the Mentice Group.

Award showcases Elekta’s and DCA’s ability to innovate new, precision technology that directly addresses the needs of cancer patients and physicians

The global respiratory syncytial virus diagnostics (RSV) market research report by Technavio forecasts the market to post a CAGR of more than 9% during the period 2019-2023.

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first patient has been dosed in the Phase 2 study of PTG-300, an injectable hepcidin mimetic peptide in development for the treatment of patients with beta thalassemia, a rare disease characterized by chronic anemia and iron overload.

The editorial board of Drug Store News (DSN) has selected GuruNanda as a winner of its prestigious Retail Excellence Award (REX) in the “natural” category.

Leviticus Cardio together with Jarvik Heart have been awarded a $950,000 grant from the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation.

BGB149 is the first therapeutic anti-AXL monoclonal antibody to enter clinical development BGB149 is BerGenBio’s second novel clinical candidate targeting AXL Phase I study will investigate safety and pharmacokinetics in healthy volunteers [09-January-2019] BERGEN, Norway, Jan. 9 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage bioph

Opsens Inc. (“Opsens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF) has been granted CE marking for its diastolic pressure algorithm (“dPR”). Opsens’ dPR algorithm has been designed to assess intracoronary pressure with the heart at rest to diagnose coronary disease without the injection of heart-stimulating medication.